Posted by Michael Wonder on 19 Jun 2024
Tafamidis meglumine for the treatment of patients with transthyretin amyloidosis with cardiomyopathy (final guidance)
19 June 2024 - NICE has published final evidence-based recommendations on the use of tafamidis meglumine (Vyndaqel) for the treatment of adults with transthyretin amyloidosis with cardiomyopathy.
Tafamidis meglumine as an option for the treatment of adults with wild type or hereditary transthyretin amyloidosis with cardiomyopathy. Tafamidis meglumine is only recommended if Pfizer provides it according to the commercial arrangement.
